BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 19472523)

  • 1. [Progress in therapy for diabetes mellitus--insulin-secretion inducing oral hypoglycemic agents].
    Nagashima K; Inagaki N
    Nihon Naika Gakkai Zasshi; 2009 Apr; 98(4):737-41. PubMed ID: 19472523
    [No Abstract]   [Full Text] [Related]  

  • 2. [Differences between oral antidiabetics].
    Bleskestad IH; Birkeland KI
    Tidsskr Nor Laegeforen; 2003 Mar; 123(6):808-9. PubMed ID: 12693123
    [No Abstract]   [Full Text] [Related]  

  • 3. [Clinical trial of AY4166].
    Kikuchi M
    Nihon Rinsho; 1997 Nov; 55 Suppl():164-70. PubMed ID: 9434462
    [No Abstract]   [Full Text] [Related]  

  • 4. [Achieving better control of blood sugar--understanding of oral hypoglycemic agents according to their characteristics in pharmacological action mechanism (discussion)].
    Kawamori R; Kadowaki T; Ishida H
    Nihon Rinsho; 2004 Apr; 62(4):831-9. PubMed ID: 15106356
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacodynamic aspects of two sulphonylurea derivatives glipizide and glibenclamide.
    Artini D; Abbiati R; Orsini G; Parenti MA; Bloch K; Daturi S; Mandelli V
    Diabetologia; 1973 Sep; ():311-6. PubMed ID: 4204091
    [No Abstract]   [Full Text] [Related]  

  • 6. [Changes in blood glucose and insulin in 4 normal subjects after administration of a single dose of glipizide and glibenclamide].
    Rizzi G; Isaia GC
    Minerva Med; 1974 Jan; 65(1):58-9. PubMed ID: 4214132
    [No Abstract]   [Full Text] [Related]  

  • 7. Unaltered glucagon secretion after seven days of sulphonylurea administration in normal subjects.
    Marco J; Valverde I
    Diabetologia; 1973 Sep; ():317-9. PubMed ID: 4204092
    [No Abstract]   [Full Text] [Related]  

  • 8. Interaction of nateglinide with K(ATP) channel in beta-cells underlies its unique insulinotropic action.
    Hu S
    Eur J Pharmacol; 2002 May; 442(1-2):163-71. PubMed ID: 12020694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The influence of various sulphonylurea derivatives on the oral glucose-tolerance tests in healthy subjects and obese and maturity-onset diabetics (author's transl)].
    Haupt E; Beyer J; Schöffling K
    Dtsch Med Wochenschr; 1974 Mar; 99(9):385-8. PubMed ID: 4208186
    [No Abstract]   [Full Text] [Related]  

  • 10. Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinide.
    Hu S; Wang S; Fanelli B; Bell PA; Dunning BE; Geisse S; Schmitz R; Boettcher BR
    J Pharmacol Exp Ther; 2000 May; 293(2):444-52. PubMed ID: 10773014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nateglinide, a non-sulfonylurea rapid insulin secretagogue, increases pancreatic islet blood flow in rats.
    Iwase M; Nakamura U; Uchizono Y; Nohara S; Sasaki N; Sonoki K; Iida M
    Eur J Pharmacol; 2005 Aug; 518(2-3):243-50. PubMed ID: 16023099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nateglinide.
    Dunn CJ; Faulds D
    Drugs; 2000 Sep; 60(3):607-615; discussion 616-7. PubMed ID: 11030470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Importance of early phase insulin secretion to intravenous glucose tolerance in subjects with type 2 diabetes mellitus.
    Kahn SE; Montgomery B; Howell W; Ligueros-Saylan M; Hsu CH; Devineni D; McLeod JF; Horowitz A; Foley JE
    J Clin Endocrinol Metab; 2001 Dec; 86(12):5824-9. PubMed ID: 11739446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Adverse effects of oral hypoglycemic agents].
    Mori Y; Sekihara H
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():325-31. PubMed ID: 12387013
    [No Abstract]   [Full Text] [Related]  

  • 15. [Therapies for newly-onset diabetic patients].
    Kawamori R
    Nihon Rinsho; 2005 Feb; 63 Suppl 2():525-32. PubMed ID: 15779435
    [No Abstract]   [Full Text] [Related]  

  • 16. Glucose-dependent and glucose-sensitizing insulinotropic effect of nateglinide: comparison to sulfonylureas and repaglinide.
    Hu S; Wang S; Dunning BE
    Int J Exp Diabetes Res; 2001; 2(1):63-72. PubMed ID: 12369728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Actions of glucagon-like peptide-1 on KATP channel-dependent and -independent effects of glucose, sulphonylureas and nateglinide.
    McClenaghan NH; Flatt PR; Ball AJ
    J Endocrinol; 2006 Sep; 190(3):889-96. PubMed ID: 17003289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [NAVIGATOR trial (nateglinide)].
    Tsujii S
    Nihon Rinsho; 2005 Feb; 63 Suppl 2():483-7. PubMed ID: 15779426
    [No Abstract]   [Full Text] [Related]  

  • 19. Long-term effects of glibenclamide and nateglinide upon pancreatic islet function in normal and diabetic rats.
    Laghmich A; Ladrière L; Malaisse-Lagae F; Malaisse WJ
    Pharmacol Res; 1999 Dec; 40(6):475-82. PubMed ID: 10660944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Possibility of ideal blood glucose control by a new oral hypoglycemic agent, N-[(trans-4-isopropylcyclohexyl)-carbonyl]-D-phenylalanine (A-4166), and its stimulatory effect on insulin secretion in animals.
    Sato Y; Nishikawa M; Shinkai H; Sukegawa E
    Diabetes Res Clin Pract; 1991 Apr; 12(1):53-9. PubMed ID: 1906797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.